- Home
- DNP vs NAMS Comparison
DNP vs NAMS Comparison
Compare DNP & NAMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DNP
- NAMS
- Stock Information
- Founded
- DNP 1986
- NAMS 2019
- Country
- DNP United States
- NAMS Netherlands
- Employees
- DNP N/A
- NAMS N/A
- Industry
- DNP Investment Managers
- NAMS Biotechnology: Pharmaceutical Preparations
- Sector
- DNP Finance
- NAMS Health Care
- Exchange
- DNP Nasdaq
- NAMS Nasdaq
- Market Cap
- DNP 3.7B
- NAMS 3.1B
- IPO Year
- DNP N/A
- NAMS N/A
- Fundamental
- Price
- DNP $10.16
- NAMS $36.14
- Analyst Decision
- DNP
- NAMS Strong Buy
- Analyst Count
- DNP 0
- NAMS 10
- Target Price
- DNP N/A
- NAMS $43.70
- AVG Volume (30 Days)
- DNP 479.6K
- NAMS 1.4M
- Earning Date
- DNP 01-01-0001
- NAMS 11-06-2025
- Dividend Yield
- DNP 7.88%
- NAMS N/A
- EPS Growth
- DNP N/A
- NAMS N/A
- EPS
- DNP 2.30
- NAMS N/A
- Revenue
- DNP $154,887,179.00
- NAMS $64,006,000.00
- Revenue This Year
- DNP N/A
- NAMS N/A
- Revenue Next Year
- DNP N/A
- NAMS N/A
- P/E Ratio
- DNP $4.26
- NAMS N/A
- Revenue Growth
- DNP 3.30
- NAMS 762.15
- 52 Week Low
- DNP $8.69
- NAMS $14.06
- 52 Week High
- DNP $10.04
- NAMS $41.47
- Technical
- Relative Strength Index (RSI)
- DNP 63.01
- NAMS 60.09
- Support Level
- DNP $9.95
- NAMS $34.34
- Resistance Level
- DNP $10.25
- NAMS $37.21
- Average True Range (ATR)
- DNP 0.08
- NAMS 2.53
- MACD
- DNP 0.02
- NAMS -0.34
- Stochastic Oscillator
- DNP 73.25
- NAMS 46.32
About DNP DNP Select Income Fund Inc.
DNP Select Income Fund Inc is a closed-ended investment management fund. The primary investment objectives of the fund are current income and long-term growth of income. Its secondary objective is capital appreciation. The Fund seeks to achieve its investment objectives by investing in the public utility industry.
About NAMS NewAmsterdam Pharma Company N.V.
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.